Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00657553 · ClinicalTrials.gov registry record · Phase 3
Preemptive Strike With Bortezomib in Multiple Myeloma Patients
A Phase 3 study, sponsored by University of Arkansas.
- Terminated
- Registry status
- Phase 3
- Development phase
- 10
- Enrollment target
NCT00657553 is a Phase 3 study that was terminated before completion, run by University of Arkansas. The registered enrollment target is 10 participants.
The verdict
NCT00657553, a Phase 3 study, was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 10 participants
- Enrollment target
Study Summary
To evaluate whether using the drug bortezomib at the start of remission will prevent relapse for a longer period of time.
Interventions
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00657553
The ClinicalTrials.gov registry entry for NCT00657553 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bortezomib is the first listed.
NCT00657553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00657553 about?
NCT00657553 is a clinical study titled "Preemptive Strike With Bortezomib in Multiple Myeloma Patients". To evaluate whether using the drug bortezomib at the start of remission will prevent relapse for a longer period of time.
What is the current status of trial NCT00657553?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 10 participants. The study started on 2008-02. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00657553?
The interventions under investigation include: Bortezomib (DRUG).
Who is sponsoring clinical trial NCT00657553?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.